[go: up one dir, main page]

YU38200A - Antagonisti integrinskog receptora - Google Patents

Antagonisti integrinskog receptora

Info

Publication number
YU38200A
YU38200A YU38200A YU38200A YU38200A YU 38200 A YU38200 A YU 38200A YU 38200 A YU38200 A YU 38200A YU 38200 A YU38200 A YU 38200A YU 38200 A YU38200 A YU 38200A
Authority
YU
Yugoslavia
Prior art keywords
receptor antagonists
integrin receptor
compounds
present
antagonists
Prior art date
Application number
YU38200A
Other languages
English (en)
Inventor
Ben Askew
Paul Coleman
Mark Duggan
Wasyl Halczenko
George Hartman
Cecilia Hunt
John Hutchinson
Robert Meissner
Michael Patane
Garry Smith
Jiabing Wang
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807382.8A external-priority patent/GB9807382D0/en
Priority claimed from GBGB9811295.6A external-priority patent/GB9811295D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU38200A publication Critical patent/YU38200A/sh

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na jedinjenja i njihove derivate, njihovu sintezu i korišćenje, kao antagonista integrinskog receptora. Preciznije, jedinjenja predmetnog pronalaska su antagonisti integrinskih receptora ανГџ3, ανГџ5, i/ili ανГџ6 i upotrebljavaju se za sprečavanje resorpcije kostiju, lečenje i prevenciju osteoporoze i sprečavanje vaskularne restenoze, dijabetične retinopatije, makularne degeneracije, angiogeneze, ateroskleroze, zapaljenja, zarastanja rana, virusnih oboljenja, rasta tumora, i metastaza.[The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors ανГџ3, ανГџ5, and/or ανГџ6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
YU38200A 1997-12-17 1998-12-14 Antagonisti integrinskog receptora YU38200A (sh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6989997P 1997-12-17 1997-12-17
GBGB9807382.8A GB9807382D0 (en) 1998-04-06 1998-04-06 Vitronectin receptor antagonists
US8320998P 1998-04-27 1998-04-27
GBGB9811295.6A GB9811295D0 (en) 1998-05-26 1998-05-26 Vitronectin receptor antagonists
US9262298P 1998-07-13 1998-07-13

Publications (1)

Publication Number Publication Date
YU38200A true YU38200A (sh) 2003-12-31

Family

ID=45477327

Family Applications (1)

Application Number Title Priority Date Filing Date
YU38200A YU38200A (sh) 1997-12-17 1998-12-14 Antagonisti integrinskog receptora

Country Status (1)

Country Link
YU (1) YU38200A (sh)

Similar Documents

Publication Publication Date Title
IL136314A0 (en) Integrin receptor antagonists
IL136495A0 (en) Integrin receptor antagonists
DE69830806D1 (de) Integrinrezeptor antagonisten
DE69720771D1 (en) Integrin antagonist
CA2277273A1 (en) Integrin antagonists
WO2000072801A3 (en) Alpha v integrin receptor antagonists
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
AU7793501A (en) Alpha v integrin receptor antagonists
WO2002090325A3 (en) Benzazepinone alpha v integrin receptor antagonists
YU38300A (sh) Antagonisti integrinskog receptora
YU38200A (sh) Antagonisti integrinskog receptora
ECSP992897A (es) Antagonistas del receptor de integrina